Cabio Biotech (Wuhan) Co., Ltd. (SHA:688089)
China
· Delayed Price · Currency is CNY 16.03
-0.03 (-0.19%)
Apr 30, 2026, 1:45 PM CST
Cabio Biotech (Wuhan) Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 50.73 | 139.29 | 124.21 | 91.37 | 64.37 | 128.58 | Upgrade
|
| Depreciation & Amortization | 62.19 | 62.19 | 55.37 | 48.35 | 27 | 23.96 | Upgrade
|
| Other Amortization | 1.44 | 1.44 | 3.13 | 1.73 | 0.57 | 0.08 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | 0 | -0.05 | -0 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 19.54 | 19.54 | 13.34 | 9.66 | 35.97 | -2.1 | Upgrade
|
| Loss (Gain) From Sale of Investments | -3.44 | -3.44 | -1.94 | -2.46 | 1.04 | -8.73 | Upgrade
|
| Provision & Write-off of Bad Debts | - | - | -4.61 | 7.03 | 15.67 | 6.12 | Upgrade
|
| Other Operating Activities | 33.73 | -9.22 | -4.58 | -6.15 | -7.06 | -0.85 | Upgrade
|
| Change in Accounts Receivable | 97.53 | 97.53 | -0.47 | -45.73 | -61.48 | -47.72 | Upgrade
|
| Change in Inventory | -48.05 | -48.05 | -39.94 | -39.59 | -9.22 | -4.87 | Upgrade
|
| Change in Accounts Payable | 13.32 | 13.32 | 29.06 | 7.51 | 100.12 | 8.99 | Upgrade
|
| Change in Other Net Operating Assets | - | - | -2.09 | -2.92 | 14.66 | - | Upgrade
|
| Operating Cash Flow | 224.45 | 270.07 | 173.04 | 68.89 | 176.4 | 103.29 | Upgrade
|
| Operating Cash Flow Growth | 38.09% | 56.07% | 151.19% | -60.95% | 70.78% | -29.20% | Upgrade
|
| Capital Expenditures | -127.32 | -144.54 | -211.6 | -297.68 | -249.47 | -173.43 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.31 | 0.32 | 0.1 | 0.27 | 0.16 | 0.19 | Upgrade
|
| Investment in Securities | 6.94 | 9.94 | -15.66 | 2.62 | -97.91 | -88.86 | Upgrade
|
| Other Investing Activities | -173.65 | -9.74 | 1.14 | 7.49 | 8.69 | 11.72 | Upgrade
|
| Investing Cash Flow | -293.72 | -144.02 | -226.03 | -287.3 | -338.53 | -250.37 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | 30 | 30 | Upgrade
|
| Long-Term Debt Issued | - | 97.86 | 18.61 | 11 | - | - | Upgrade
|
| Total Debt Issued | 182.96 | 97.86 | 18.61 | 11 | 30 | 30 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | - | -30 | Upgrade
|
| Long-Term Debt Repaid | - | -33.28 | -22.96 | -31.35 | -0.99 | -0.97 | Upgrade
|
| Total Debt Repaid | -28.58 | -33.28 | -22.96 | -31.35 | -0.99 | -30.97 | Upgrade
|
| Net Debt Issued (Repaid) | 154.38 | 64.58 | -4.34 | -20.35 | 29.01 | -0.97 | Upgrade
|
| Issuance of Common Stock | - | - | - | 6.39 | - | - | Upgrade
|
| Common Dividends Paid | -36.54 | -35.87 | -34.02 | -36.58 | -39.85 | -39.87 | Upgrade
|
| Other Financing Activities | -30.04 | -32.31 | - | 16.53 | - | 1.47 | Upgrade
|
| Financing Cash Flow | 87.8 | -3.6 | -38.36 | -34.02 | -10.83 | -39.37 | Upgrade
|
| Foreign Exchange Rate Adjustments | -1.7 | 0.59 | 0.9 | 1.46 | 7.02 | -1.81 | Upgrade
|
| Net Cash Flow | 16.84 | 123.04 | -90.44 | -250.96 | -165.94 | -188.26 | Upgrade
|
| Free Cash Flow | 97.13 | 125.53 | -38.55 | -228.79 | -73.07 | -70.14 | Upgrade
|
| Free Cash Flow Margin | 23.23% | 22.29% | -6.94% | -51.55% | -16.86% | -19.98% | Upgrade
|
| Free Cash Flow Per Share | 0.58 | 0.75 | -0.23 | -1.35 | -0.43 | -0.42 | Upgrade
|
| Cash Income Tax Paid | 28.86 | 41.07 | 29.66 | 49.04 | 26.62 | 39.54 | Upgrade
|
| Levered Free Cash Flow | 112.49 | 108.66 | -128.6 | -342.35 | -139.91 | -135.83 | Upgrade
|
| Unlevered Free Cash Flow | 113.23 | 108.66 | -128.35 | -341.98 | -139.68 | -135.61 | Upgrade
|
| Change in Working Capital | 60.27 | 60.27 | -11.87 | -80.6 | 38.85 | -43.77 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.